clinical trial · NCT06987539
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Amgen·phase2·recruiting·n = 15
Generalized Myasthenia GravisInebilizumab
brief summary
The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of inebilizumab administered in pediatric participants with gMG, and to assess the safety and tolerability of inebilizumab administered in pediatric participants with gMG.
started
Apr 30, 2026
primary completion
Mar 13, 2030
completion
Mar 13, 2030
last updated
Apr 7, 2026
official title
A Phase 2 Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age With Generalized Myasthenia Gravis (gMG)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol